Lipum AB (publ) ("Lipum" or the "Company") announces that the subscription period in the Company’s capital raising begins today and runs until July 18, 2023.

Lipum wants to inform that Erik Penser Bank has published a company presentation and an interview with the Company's CEO, Einar Pontén. The purpose of the company presentation and interview is to provide shareholders and other interested stakeholders with a deeper insight into the Company's operations.

The company presentation is uploaded on Erik Penser Bank's YouTube channel and can be viewed through this link: https://youtu.be/Nz51xC-nWxE

The interview is uploaded on Erik Penser Bank's YouTube channel and can be viewed through this link: https://youtu.be/exAHnh6p4EI

Contacts
Einar Pontén, CEO
E-post: einar.ponten@lipum.se
Mobile: +46 70 578 34 95
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
The subscription period in Lipum’s rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank

The subscription period in Lipum’s rights issue begins today and the CEO has participated in a company presentation and CEO interview with Erik Penser Bank